Geode Capital Management
DNTH icon

Geode Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Geode Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.9M Buy
916,211
+239,553
+35% +$13.9M ﹤0.01% 1246
2025
Q4 		$27.9M Buy
676,658
+140,243
+26% +$5.44M ﹤0.01% 1834
2025
Q3 		$21.1M Buy
536,415
+51,515
+11% +$1.32M ﹤0.01% 1974
2025
Q2 		$9.04M Sell
484,900
-32,118
-6% -$603K ﹤0.01% 2428
2025
Q1 		$9.38M Buy
517,018
+30,755
+6% +$678K ﹤0.01% 2331
2024
Q4 		$10.6M Buy
486,263
+1,142
+0.2% +$29.4K ﹤0.01% 2344
2024
Q3 		$13.3M Sell
485,121
-13,799
-3% -$384K ﹤0.01% 2205
2024
Q2 		$12.9M Buy
498,920
+424,520
+571% +$10.2M ﹤0.01% 2170
2024
Q1 		$2.23M Buy
74,400
+29,221
+65% +$635K ﹤0.01% 3073
2023
Q4 		$470K Buy
45,179
+18,838
+72% +$208K ﹤0.01% 3640
2023
Q3 		$360K Buy
26,341
+3,985
+18% +$50.2K ﹤0.01% 3730
2023
Q2 		$271K Hold
22,356
– – ﹤0.01% 3904
2023
Q1 		$284K Hold
22,356
– – ﹤0.01% 3883
2022
Q4 		$141K Buy
22,356
+454
+2% +$8.04K ﹤0.01% 4257
2022
Q3 		$494K Buy
21,902
+410
+2% +$11.2K ﹤0.01% 3737
2022
Q2 		$412K Sell
21,492
-15,589
-42% -$385K ﹤0.01% 3866
2022
Q1 		$1.72M Buy
37,081
+2,585
+7% +$141K ﹤0.01% 3334
2021
Q4 		$2.44M Buy
34,496
+1,479
+4% +$149K ﹤0.01% 3275
2021
Q3 		$3.85M Buy
33,017
+1,568
+5% +$183K ﹤0.01% 3065
2021
Q2 		$4.92M Buy
31,449
+6,212
+25% +$1.14M ﹤0.01% 2922
2021
Q1 		$4.78M Buy
25,237
+7,244
+40% +$1.22M ﹤0.01% 2811
2020
Q4 		$2.26M Sell
17,993
-34
-0.2% -$3.85K ﹤0.01% 3018
2020
Q3 		$1.96M Buy
18,027
+532
+3% +$63K ﹤0.01% 2880
2020
Q2 		$2.1M Buy
17,495
+555
+3% +$78.2K ﹤0.01% 2810
2020
Q1 		$1.7M Buy
16,940
+775
+5% +$144K ﹤0.01% 2757
2019
Q4 		$3.92M Buy
16,165
+946
+6% +$177K ﹤0.01% 2603
2019
Q3 		$2.5M Buy
15,219
+201
+1% +$38.2K ﹤0.01% 2803
2019
Q2 		$3.54M Buy
15,018
+7,459
+99% +$1.84M ﹤0.01% 2610
2019
Q1 		$1.99M Buy
7,559
+6,200
+456% +$1.07M ﹤0.01% 2858
2018
Q4 		$123K Buy
1,359
+408
+43% +$55.6K ﹤0.01% 3825
2018
Q3 		$182K Buy
+951
New +$200K ﹤0.01% 3787

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management's DNTH Position: Q1 2026 in Review

Geode Capital Management increased its Dianthus Therapeutics (DNTH) stake by 35% in Q1 2026, buying an estimated $13.9M and bringing the position to 916,211 shares worth $76.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1246.

Geode Capital Management first reported a position in DNTH in Q3 2018 and has held it in 31 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Geode Capital Management held 916,211 shares of Dianthus Therapeutics worth $76.9M as of Q1 2026.
  • Geode Capital Management bought 239,553 Dianthus Therapeutics shares in Q1 2026, an estimated $13.9M.
  • Dianthus Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1246 holding.
  • Geode Capital Management first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.